Litfulo (ritlecitinib)

P=N/A, N=150, Completed, The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

Importantly, no patients in both groups experienced SALT worsening or treatment-related adverse events. Our findings highlighted that ritlecitinib is highly effective especially in adolescent JAKi-naïve AA, and although the clinical effect may be limited in JAKi-experienced patients, switching from baricitinib to ritlecitinib remains one of the viable options due to its low risk of disease exacerbation.

P=N/A, N=300, Not yet recruiting, Pfizer | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026

The efficacy of ritlecitinib, an oral Janus kinase 3/TEC family inhibitor, has been demonstrated in the Allegro clinical trials...The US Food and Drug Administration issued black box warnings, citing increased risks of major adverse cardiovascular events, malignancies, venous thromboembolism (VTE) and mortality based on data from tofacitinib, baricitinib and upadacitinib in rheumatoid arthritis...The patient received intravenous broad-spectrum antibiotics for sepsis of unknown origin, hydrocortisone and vasopressor support for hypotension. She was anticoagulated with dalteparin and transitioned to apixaban as per respiratory advice for unprovoked pulmonary emboli...This case highlights a probable severe adverse event associated with ritlecitinib therapy, including pulmonary emboli and infection of unidentified source, associated with new-onset atrial fibrillation and acute kidney injury in a patient without known risk factors for VTE. Ongoing pharmacovigilance is essential to understand the potential risks associated with Janus kinase inhibitors in AA treatment.

P2, N=240, Recruiting, Pfizer | Not yet recruiting --> Recruiting

P=N/A, N=3000, Recruiting, Pfizer | Not yet recruiting --> Recruiting | Trial completion date: Sep 2030 --> Mar 2030 | Trial primary completion date: Sep 2030 --> Mar 2030

P2, N=40, Recruiting, Massachusetts General Hospital | Trial completion date: Aug 2025 --> Dec 2025 | Trial primary completion date: Aug 2025 --> Dec 2025

P2, N=240, Not yet recruiting, Pfizer

P2, N=200, Recruiting, Pfizer | Not yet recruiting --> Recruiting

P=N/A, N=300, Not yet recruiting, Pfizer

In a benchmark for ritlecitinib, we found that scaffolds NS_1813 and NS_2063 showed better binding affinities, with 20 compounds meeting our selection criteria...From these, six lead compounds were chosen for detailed molecular dynamics and docking pose analyses to assess their conformational stability and binding interactions within the JAK3 active site. These compounds are promising candidates for further development, including chemical synthesis, followed by in vitro and in vivo testing to evaluate their potential as JAK3-targeting therapeutic agents.

P2, N=200, Not yet recruiting, Pfizer